TNM cancer staging and type 2 diabetes – 179963

Описание: Video abstract of review paper “TNM cancer staging: can it help develop a novel staging system for type 2 diabetes?” published in the open access Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy journal by Dar MS and Beg SA.

Film images used in this video abstract are stock media provided by Pond5. All participants of this video gave consent for their images to be used.

Abstract: Type 2 diabetes (DM2) constitutes 90%–95% of the diabetes cases and is increasing
at an alarming rate in the world. The Centers for Disease Control and Prevention (CDC) estimates
that more than 29 million people in the United States have diabetes, which often causes
mortality from macrovascular complications and morbidity from microvascular complications.
Despite these troubling facts, there is currently no widely accepted staging system for DM2
like there is for cancer. TNM oncologic staging has taken a complex condition like cancer and
conveyed likelihood of survival in simple alpha-numeric terms that both patients and providers
can understand. Oncology is now entering the era of precision medicine where cancer treatment
is increasingly being tailored to each patient’s cancer. In contrast, DM2 lacks a staging system
and remains a largely invisible disease even though it kills more Americans and costs more to
treat than cancer. Is a comparable staging system for DM2 possible? We propose the Diabetes
Staging System for DM2 that utilizes macrovascular events, microvascular complications,
estimated glomerular filtration rate (GFR), and hemoglobin A1C to stage DM2.

Read the review paper here: https://www.dovepress.com/tnm-cancer-...